Tag: icd

Atrial Fibrillation Travel Tips

No need to feel anxious about hitting the road when you have atrial fibrillation (AFib). “As long as you’re getting good medical care, traveling with...

Evidence Builds for iPhone 12 Interference With Cardiac Devices

Further evidence that powerful magnets in some Apple iPhones can interfere with cardiac implantable electronic devices (CIEDs) comes from a small study that also suggests...

Underlying Heart Rhythm, Not ICD Shocks, Drives Mortality

Combined data from five implantable cardioverter-defibrillator (ICD) trials suggest that it is the underlying arrhythmic disorder, rather than the ICD therapy itself, that affects mortality...

New-Onset Anxiety, Depression an Ongoing Risk for ICD Patients

Testing for anxiety or depression should be offered periodically — perhaps for months to years — to patients with implantable cardioverter defibrillators (ICD), not just...

Trade-offs Between S-ICD, Transvenous ICDs Shown in EFFORTLESS

One of the largest and longest follow-ups of patients implanted with the subcutaneous-lead implantable cardioverter defibrillator (S-ICD), now marketed as the EMBLEM S-ICD (Boston Scientific),...

Abandoned Cardiac Device Leads Don’t Rule Out MRI

Data from an observational cohort study suggest that the presence of abandoned leads in patients with cardiac implantable electronic devices (CIEDs) should no longer be...

CMS Teams With ACC to Make Quality Measures More Relevant

The Centers for Medicare & Medicaid Services (CMS) has partnered with the American College of Cardiology (ACC) to include several National Cardiovascular Data Registry (NCDR)...

Cardiac Device Interference Risk ‘Low’ With Smartphones, Watches

The risk for electromagnetic interference (EMI) of smartphones and smartwatches with cardiovascular implantable electronic devices (CIEDs) is low, new research suggests. Investigators tested CIEDs in...

For Some, Sacubitril/Valsartan May Obviate Need for ICD

After 6 months of therapy with the combination drug sacubitril/valsartan (S/V; Entresto, Novartis), one quarter of primary prevention patients with left heart failure and an...